Literature DB >> 28114814

Transcriptomic effects of metformin in skeletal muscle arteries of obese insulin-resistant rats.

Jaume Padilla1,2,3, Pamela K Thorne4, Jeffrey S Martin5,6, R Scott Rector1,7,8, Sadia Akter9, J Wade Davis9,10,11, M Harold Laughlin3,4,12, Nathan T Jenkins13.   

Abstract

We examined the effects of metformin, a commonly used antidiabetic drug, on gene expression in multiple arteries. Specifically, transcriptional profiles of feed arteries and second branch order arterioles in the soleus, gastrocnemius, and diaphragm muscles as well as aortic endothelial scrapes were examined from obese insulin-resistant Otsuka Long-Evans Tokushima Fatty rats treated with ( n = 9) or without ( n = 10) metformin from 20 to 32 weeks of age. Metformin-treated rats exhibited a reduction in body weight, adiposity, and HbA1c ( P < 0.05). The greatest number of differentially expressed genes (FDR < 15%) between those treated with and without metformin was found in the red gastrocnemius 2a arterioles (93 genes), followed by the diaphragm 2a arterioles (62 genes), and soleus 2a arterioles (15 genes). We also found that two genes were differentially expressed in aortic endothelial cells (LETMD1 and HMGCS2, both downregulated), one gene in the gastrocnemius feed artery (BLNK, downregulated), and no genes in the soleus and diaphragm feed arteries and white gastrocnemius 2a arterioles. No single gene was altered by metformin across all vessels examined. This study provides evidence that metformin treatment produces distinct gene expression effects throughout the arterial tree in a rat model of obesity and insulin resistance. Genes whose expression was modulated with metformin do not appear to have a clear connection with its known mechanisms of action. These findings support the notion that vascular gene regulation in response to oral pharmacological therapy, such as metformin, is vessel specific. Impact statement This study provides evidence that metformin treatment produces artery-specific gene expression effects. The genes whose expression was modulated with metformin do not appear to have a clear connection with its known mechanisms of action.

Entities:  

Keywords:  RNA sequencing; diabetes; gene expression; skeletal muscle resistance arteries

Mesh:

Substances:

Year:  2017        PMID: 28114814      PMCID: PMC5685263          DOI: 10.1177/1535370216689825

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  28 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  Exercise-induced differential changes in gene expression among arterioles of skeletal muscles of obese rats.

Authors:  M Harold Laughlin; Jaume Padilla; Nathan T Jenkins; Pamela K Thorne; Jeffrey S Martin; R Scott Rector; Sadia Akter; J Wade Davis
Journal:  J Appl Physiol (1985)       Date:  2015-07-16

4.  Identification of genes whose expression is altered by obesity throughout the arterial tree.

Authors:  Jaume Padilla; Nathan T Jenkins; Pamela K Thorne; Jeffrey S Martin; R Scott Rector; J Wade Davis; M Harold Laughlin
Journal:  Physiol Genomics       Date:  2014-09-30       Impact factor: 3.107

5.  Impact of exercise training on endothelial transcriptional profiles in healthy swine: a genome-wide microarray analysis.

Authors:  Jaume Padilla; Grant H Simmons; J Wade Davis; Jeffrey J Whyte; Theodore W Zderic; Marc T Hamilton; Douglas K Bowles; M Harold Laughlin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-27       Impact factor: 4.733

6.  Effects of endurance exercise training, metformin, and their combination on adipose tissue leptin and IL-10 secretion in OLETF rats.

Authors:  Nathan T Jenkins; Jaume Padilla; Arturo A Arce-Esquivel; David S Bayless; Jeffrey S Martin; Heather J Leidy; Frank W Booth; R Scott Rector; M Harold Laughlin
Journal:  J Appl Physiol (1985)       Date:  2012-09-27

7.  Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.

Authors:  Melissa A Linden; Justin A Fletcher; E Matthew Morris; Grace M Meers; Monica L Kearney; Jacqueline M Crissey; M Harold Laughlin; Frank W Booth; James R Sowers; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

8.  Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine.

Authors:  Jaume Padilla; Nathan T Jenkins; Sewon Lee; Hanrui Zhang; Jian Cui; Mozow Y Zuidema; Cuihua Zhang; Michael A Hill; James W Perfield; Jamal A Ibdah; Frank W Booth; J Wade Davis; M Harold Laughlin; R Scott Rector
Journal:  Physiol Genomics       Date:  2013-04-16       Impact factor: 3.107

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.

Authors:  Anila K Madiraju; Derek M Erion; Yasmeen Rahimi; Xian-Man Zhang; Demetrios T Braddock; Ronald A Albright; Brett J Prigaro; John L Wood; Sanjay Bhanot; Michael J MacDonald; Michael J Jurczak; Joao-Paulo Camporez; Hui-Young Lee; Gary W Cline; Varman T Samuel; Richard G Kibbey; Gerald I Shulman
Journal:  Nature       Date:  2014-05-21       Impact factor: 49.962

View more
  1 in total

1.  Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals.

Authors:  Monta Ustinova; Ivars Silamikelis; Ineta Kalnina; Laura Ansone; Vita Rovite; Ilze Elbere; Ilze Radovica-Spalvina; Davids Fridmanis; Jekaterina Aladyeva; Ilze Konrade; Valdis Pirags; Janis Klovins
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.